Evidence map›Paper›PMID 28634642›Full record

ArticleEuropean journal of clinical pharmacology2017

Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study.

Nazanin Abolhassani, Julien Castioni, Pedro Marques-Vidal, Peter Vollenweider, Gérard Waeber

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nazanin AbolhassaniDepartment of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Julien CastioniDepartment of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Pedro Marques-VidalDepartment of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland. Pedro-Manuel.Marques-Vidal@chuv.ch.
Peter VollenweiderDepartment of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Gérard WaeberDepartment of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aimed to assess the prevalence, the change, and the determinants of change in polypharmacy in a population-based sample.

methodsBaseline (2003-2006) and follow-up (2009-2012) data are from 4679 participants aged between 35 and 75 years (53.5% women, mean age 52.6 ± 10.6 years) from the population of Lausanne, Switzerland. Polypharmacy was defined by the regular use of ≥5 drugs. Four categories of change were defined: never (no polypharmacy at baseline and follow-up), initiating (no polypharmacy at baseline but at follow-up), maintaining, or quitting.

resultsPolypharmacy increased from 7.7% at baseline to 15.3% at follow-up. Cardiovascular drugs were the most prescribed medicines at baseline and follow-up. Gender, age, obesity, smoking, previously diagnosed hypertension, or diabetes or dyslipidemia were significantly and independently associated with initiating and maintaining polypharmacy.

conclusionIn a population-based sample, prevalence of polypharmacy doubled over a 5.6-year period. The main determinants of initiating polypharmacy were age, overweight and obesity, smoking status, and previously diagnosed cardiovascular risk factors.

Indexed as

PolypharmacyAdultAgedAnalgesicsCardiovascular AgentsDiabetes MellitusDyslipidemiasFemaleHumansHypertensionHypoglycemic AgentsLife StyleMaleMiddle AgedOverweightPrevalenceAnalgesicsCardiovascular AgentsHypoglycemic AgentsPsychotropic DrugsDeterminantsGeneral populationPolypharmacySwitzerlandTrends

Identifiers

PMID28634642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.